At Profacgen, we offer a comprehensive portfolio of PEGylation products and services designed to enhance the stability, solubility, and pharmacological properties of proteins, peptides, antibody-drug conjugates, oligonucleotides, and small-molecule drugs. As a synthetic polymer with exceptional hydrophilicity, biocompatibility, and low immunogenicity, polyethylene glycol (PEG) has become an indispensable tool in modern biopharmaceutical development, with a proven track record of improving therapeutic outcomes across multiple drug modalities.
PEGylation has been successfully employed in numerous regulatory agencies-approved drugs to date, extending circulation half-life, reducing immunogenicity, masking proteolytic cleavage sites, and improving the aqueous solubility of therapeutic molecules that would otherwise face significant formulation challenges. Originally developed for protein modification in the 1970s, PEGylation technology has since expanded to encompass peptides, oligonucleotides, antibody-drug conjugates, and most recently small-molecule drugs, opening new avenues for pharmacokinetic optimization and therapeutic index improvement across virtually all pharmaceutical modalities.
With years of experience in bioconjugation chemistry, Profacgen provides quality solutions ranging from individual activated PEG reagents to comprehensive, end-to-end PEGylation service packages. Whether you need a standard catalog product for research evaluation or a fully customized conjugation and manufacturing program, our team delivers tailored solutions that meet your specific molecular targets, development stage, and regulatory requirements.
PEGylation involves the covalent attachment of polyethylene glycol chains to therapeutic molecules, creating a hydrophilic steric barrier that modulates pharmacokinetic and pharmacodynamic properties through multiple mechanisms. The attached PEG chain increases the effective hydrodynamic radius of the conjugate, reducing renal glomerular filtration and extending circulating half-life. The hydrophilic PEG shield also masks antigenic epitopes, reducing recognition by the immune system and lowering immunogenicity. Additionally, PEGylation can block proteolytic cleavage sites, hinder aggregation-prone surfaces, and improve the solubility of hydrophobic therapeutic agents.
Linear PEG consists of a single chain of ethylene glycol repeating units terminated with a functional group for conjugation. Linear PEG reagents provide single, low PEG density modification per attachment point and are suitable for applications where minimal structural perturbation of the therapeutic protein is essential. The well-defined structure and established regulatory history of linear PEG conjugates make this the default choice for many first-generation PEGylation programs.
Branched and multi-arm PEG attach multiple PEG chains to a single point of attachment, creating a higher local PEG density and more effective steric shielding per conjugation site. Branched PEGs (such as Y-shaped or forked architectures) can deliver enhanced circulation extension and improved shielding at lower degrees of substitution compared to linear analogs. Multi-arm PEGs (4-arm, 8-arm) are particularly valuable for surface coating, hydrogel formation, and applications requiring high local PEG density. Branched and multi-arm architectures may be advantageous when mono-PEGylation is preferred but enhanced pharmacokinetic benefits are required.
Figure 1. Different linking methods, including linear, armed, Y-shaped, and comb-like connections, can be
used to construct different PEG variants. (Aldaais, 2023)
The attachment of PEG to proteins typically targets amino acid side chains with high nucleophilic reactivity, including lysine ε-amines, cysteine thiols, and N-terminal α-amines. To preserve biological activity and simplify downstream purification, mono-PEGylation (attachment of a single PEG chain per protein molecule) and site-specific PEGylation (directed conjugation at a defined location) are increasingly preferred. Site-specific approaches deliver PEG reagents to carefully chosen locations that minimize disruption of binding interfaces and active sites, reduce structural heterogeneity, and simplify regulatory pathways by yielding a more homogeneous product.
Profacgen offers two complementary PEGylation offerings to support your development pipeline:
End-to-end PEGylation development services covering strategic design, conjugation chemistry optimization, purification process development, and comprehensive analytical characterization.
High-purity, functionalized PEG reagents for in-house bioconjugation, available in monofunctional, homobifunctional, heterobifunctional, and multi-arm architectures.
Background:
A biopharmaceutical company developed a potent peptide agonist for a metabolic disease target with excellent in vitro activity but a circulating half-life of only 12 minutes due to rapid renal filtration and proteolytic degradation, making clinical development impractical without modification.
Approach:
Profacgen evaluated three PEGylation strategies in parallel: (1) N-terminal PEGylation with linear PEG via reductive amination; (2) cysteine-directed PEGylation with maleimide-PEG at an engineered C-terminal cysteine; and (3) branched Y-shaped PEG conjugation at the N-terminus. PEG molecular weights of 20 kDa, 30 kDa, and 40 kDa were screened for each approach. Conjugates were evaluated for binding affinity, in vitro activity, plasma stability, and pharmacokinetics in rodents.
Outcome:
The cysteine-directed 40 kDa linear PEG conjugate emerged as the optimal candidate, retaining 85% of the parent peptide's receptor-binding affinity and full agonist activity. The PEGylated peptide exhibited a circulating half-life of 62 hours in rats (300-fold extension) and maintained sustained pharmacodynamic activity for 72 hours after a single subcutaneous dose. The homogeneous, site-specific conjugation simplified manufacturing and regulatory pathways. The candidate advanced to Phase I clinical trials within 18 months of project initiation.
Background:
An oncology program required an antibody-drug conjugate with improved therapeutic index. Conventional ADCs using hydrophobic linker-payloads suffered from aggregation at high drug-to-antibody ratios and rapid clearance by the reticuloendothelial system.
Approach:
Profacgen designed a PEG-containing linker architecture in which a hydrophilic PEG8 spacer was incorporated between the antibody attachment site and the cytotoxic payload. The PEG spacer was conjugated to engineered surface cysteines on the antibody via maleimide chemistry, providing a site-specific, homogeneous conjugation. The PEG moiety increased the hydrophilicity of the linker-payload, reduced aggregation propensity, and shielded the hydrophobic drug from recognition by clearance mechanisms.
Outcome:
The PEG-containing ADC achieved a drug-to-antibody ratio of 4 with <3% aggregation, compared to 15% aggregation for the non-PEGylated control at the same DAR. Circulating half-life in mice improved 2.5-fold (72 h vs. 29 h). In vivo efficacy studies in a patient-derived xenograft model demonstrated complete tumor regression at 5 mg/kg with no significant body weight loss, compared to only partial response and dose-limiting toxicity for the non-PEGylated ADC at the same dose. The PEG linker technology was subsequently applied to three additional ADC programs.
Discuss Your PEGylation Project
References:
Fill out this form and one of our experts will respond to you within one business day.